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Abstract
Background: Although lifestyle factors have been studied in relation to individual non-communicable diseases
(NCDs), their association with development of a subsequent NCD, defined as multimorbidity, has been scarcely
investigated. The aim of this study was to investigate associations between five lifestyle factors and incident
multimorbidity of cancer and cardiometabolic diseases.
Methods: In this prospective cohort study, 291,778 participants (64% women) from seven European countries,
mostly aged 43 to 58 years and free of cancer, cardiovascular disease (CVD), and type 2 diabetes (T2D) at
recruitment, were included. Incident multimorbidity of cancer and cardiometabolic diseases was defined as
developing subsequently two diseases including first cancer at any site, CVD, and T2D in an individual. Multi-state
modelling based on Cox regression was used to compute hazard ratios (HR) and 95% confidence intervals (95% CI)
of developing cancer, CVD, or T2D, and subsequent transitions to multimorbidity, in relation to body mass index
(BMI), smoking status, alcohol intake, physical activity, adherence to the Mediterranean diet, and their combination
as a healthy lifestyle index (HLI) score. Cumulative incidence functions (CIFs) were estimated to compute 10-year
absolute risks for transitions from healthy to cancer at any site, CVD (both fatal and non-fatal), or T2D, and to
subsequent multimorbidity after each of the three NCDs.
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Results: During a median follow-up of 11 years, 1910 men and 1334 women developed multimorbidity of cancer
and cardiometabolic diseases. A higher HLI, reflecting healthy lifestyles, was strongly inversely associated with
multimorbidity, with hazard ratios per 3-unit increment of 0.75 (95% CI, 0.71 to 0.81), 0.84 (0.79 to 0.90), and 0.82
(0.77 to 0.88) after cancer, CVD, and T2D, respectively. After T2D, the 10-year absolute risks of multimorbidity were
40% and 25% for men and women, respectively, with unhealthy lifestyle, and 30% and 18% for men and women
with healthy lifestyles.
Conclusion: Pre-diagnostic healthy lifestyle behaviours were strongly inversely associated with the risk of cancer
and cardiometabolic diseases, and with the prognosis of these diseases by reducing risk of multimorbidity.
Keywords: Healthy lifestyle, Obesity, Cancer and cardiometabolic multimorbidity, Cancer, Cardiovascular disease,
Diabetes, Prevention
Introduction
Improvements in longevity have increased the likeli-
hood for an individual to develop two or more diseases,
a phenomenon commonly referred to as multimorbidity
[1, 2]. Cardiovascular diseases (CVD), including heart
disease and stroke, type 2 diabetes (T2D), and cancer
are particularly relevant as they are the most common
non-communicable diseases (NCDs) and represent
major causes of morbidity, disability, and impaired
quality of life [3]. Owing to improvements in health
care, many individuals will survive their first NCD and
multimorbidity is becoming the norm for people with
chronic disease [4]. In 2016, there was an estimated
15.5 million cancer survivors living in the USA, of
whom 60% of survivors aged 85 years and older had at
least one comorbid condition prior to cancer and
among the top three prevalent comorbid conditions
were T2D and CVD [5]. In addition, data from Scotland
have revealed that approximately 65% of individuals
older than 65 years were multimorbid and more than
half of all those with multimorbidity were younger than
65 years [4]. Multimorbidity is now considered a global
health care priority [6].
The study of individual diseases dominates medical
research, and epidemiological studies have generally
investigated the occurrence of single adverse events as
an outcome (e.g. incidence of cancer). This approach
provides sound evidence for exposure-disease associa-
tions and has greatly advanced our understanding of
disease aetiology [7]. The 2013–2020 World Health
Organization (WHO) Global Action Plan for the Pre-
vention and Control of NCDs aimed to prevent and
control major NCDs and their key risk factors includ-
ing obesity, tobacco use, physical inactivity, harmful
alcohol use, and unhealthy diets [8, 9]. However, lim-
ited evidence exists on how established risk factors
for single NCDs are related to clustering of NCDs
within individuals. This evidence has the potential to
broaden the scope of public health recommendations
encompassing patients affected by chronic conditions,
and to inform on combined interventions to prevent
multiple NCDs. A recent randomized controlled trial
showed that a multi-domain intervention reduced the
risk of accumulating new chronic diseases most ef-
fectively in participants who already were affected by
at least one chronic disorder at baseline [10]. How-
ever, few studies to date have investigated the associ-
ation of lifestyle factors with multimorbidity [11–16],
in particular in combination with cancer [11, 14, 15],
and disease trajectories have not been studied.
The aim of this study was to investigate associations
between five lifestyle factors and risk of cancer-
cardiometabolic multimorbidity defined as developing
subsequently at least two morbidities including first can-
cer at any site, cardiovascular diseases (CVD), and type 2
diabetes (T2D) in an individual. We also estimated 10-
year absolute risks for these outcomes.
Methods
Study population and design
The EPIC study is an ongoing multi-centre cohort that
was initiated from 1992 to 2000 in 23 recruitment cen-
tres across 10 European countries (Denmark, France,
Germany, Greece, Italy, the Netherlands, Norway, Spain,
Sweden, and the UK) and was designed to investigate
the relationship between nutrition, lifestyle, genetics, and
cancer and other chronic diseases [17]. More than 520,
000 adults (70% women) mostly aged 35–70 were re-
cruited and have been followed up for cancer events and
mortality status. In addition, two nested cohort studies
with a focus on T2D and CVD were established which
were used for outcome ascertainment in the current
study: EPIC-InterAct is a case-cohort study that aimed
to investigate the association between genetic and life-
style factors and incident T2D events ascertained be-
tween 1992 and 2007 in all EPIC countries with the
exception of Norway and Greece [18]. Similarly, EPIC-
CVD is the component of the EPIC study which investi-
gated the aetiology of cardiovascular disease, with a
case-cohort study design that assessed incident coronary
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heart disease (CHD) and stroke events in EPIC from
1992 to 2010 in all EPIC countries except France [19].
Assessment of lifestyle exposure
Diet, including alcohol intake, was assessed at baseline
using validated country-specific or centre-specific dietary
questionnaires designed to capture habitual consump-
tion over the preceding year [17]. Information on
smoking status and duration, educational attainment,
menopausal status (women), and use of hormones in
post-menopausal women was obtained using lifestyle
questionnaires [17]. Height and weight (self-reported in
the Oxford centre, measured elsewhere) were used to
compute body mass index (BMI, kg/m2) [17]. Physical
activity was assessed at baseline using a specific ques-
tionnaire about occupational and recreational activity,
from which a validated index (Cambridge Index) was
computed to capture all physical activity domains [20].
Adherence to a healthy diet was assessed with the
modified relative Mediterranean Diet Score (mrMDS), a
variation of the original Mediterranean Diet Score re-
placing olive oil with vegetable oil [21]. The mrMDS is
an 18-point linear score that incorporates 9 nutritional
components of the Mediterranean diet, including com-
ponents presumed to be beneficial (vegetables, legumes,
fruit and nuts, cereals, fish and seafood, vegetable oil,
and moderate alcohol consumption) and potentially
harmful (meat and meat products and dairy products).
Each mrMDS component was estimated in grams per
1000 kcal to express intake as energy density [21]. All
components were divided into country-specific tertiles
and scores 0 to 2 were summed up, with increasing
scores for healthier diet (range 0–18).
Healthy lifestyle index
The five lifestyle factors were summarized in a com-
posite healthy lifestyle index (HLI) as described previ-
ously [22]. Briefly, categories of each factor were
scored from 0 to 4, with higher points indicating a
healthier behaviour for, in turn, smoking (never smoked =
4, former smoker = 2, current smoker = 0), alcohol intake
(< 6 g/day = 4, 6.0–11.9 g/day = 3, 12.0–24.9 g/day = 2,
24.0–59.9 g/day = 1, ≥ 60 g/day = 0), physical activity (ac-
tive = 4, moderately active = 3, moderately inactive = 1, in-
active = 0), BMI (22–23.9 kg/m2 = 4, < 22 = 3, 24–25.9 = 2,
26–29.9 = 1, ≥ 30 = 0), and diet (scoring 4 to 0 points for
top to bottom quintile of the mrMDS). The HLI ranged
from 0 to 20. We also computed a simplified version of
the HLI (sHLI) by giving one point if the healthy defin-
ition of a lifestyle factor was met, according to healthy life-
style recommendations, and 0 otherwise. The scoring of
the sHLI is shown in Additional file 1: Table S1.
Outcome assessment
Cancers at any site (excluding non-melanoma skin can-
cer) that occurred among the EPIC cohort were assessed
by population cancer registries in Denmark, Italy, The
Netherlands, Spain, Sweden, and the UK, and by a com-
bination of methods including health insurance records,
cancer and pathology registries, and by active follow-up
in Germany. Data on cancer incidence were coded ac-
cording to the International Classification of Diseases
for Oncology (ICD-O-3). Data on total mortality was
collected at the recruitment centres through mortality
registries and used for censoring [17].
Incident T2D cases were ascertained at each partici-
pating centre by a combination of self-report, linkage to
primary care registers, secondary-care registers, medica-
tion use (drug registers), hospital admissions, and mor-
tality data. Incident T2D cases in Denmark and Sweden
were not self-reported but were defined according to
local and national diabetes and pharmaceutical registries.
To increase the specificity of the case definition for cen-
tres other than those from Denmark and Sweden, fur-
ther evidence was sought for all cases with information
on incident T2D from fewer than two independent
sources at a minimum, including individual medical re-
cords review in some centres [18].
Coronary disease endpoints were defined as any CHD,
comprised of myocardial infarction (MI) (ICD-10 codes:
I21, I22), angina (I20), or other CHD (I23-I25). Cerebrovas-
cular events were ascertained and validated using the same
methods as for coronary events and included haemorrhagic
stroke (I60-I61), ischemic stroke (I63), unclassified stroke
(I64), and other acute cerebrovascular events (I62, I65-69,
F01). First non-fatal coronary events were ascertained by
different methods depending on the follow-up procedures
by centre, using active follow-up through questionnaires or
linkage with morbidity and hospital registries, or both [19].
Validation of suspected events was performed on all ascer-
tained case events (Denmark, Germany, Italy, and Spain) or
on a subset of events (Sweden, the Netherlands, and UK).
Validation was performed by retrieving and assessing med-
ical records or hospital notes, contact with medical profes-
sionals, retrieving and assessing death certificates, or verbal
autopsy. Angina was not assessed as a first CHD outcome
in the Italian EPIC centres of Varese, Torino, and in
Germany, Sweden, and Denmark. Each outcome was classi-
fied as fatal or non-fatal with the exception of angina, which
is never fatal. In an attempt to harmonize the definition of
fatal CVD across centres, non-fatal and fatal events occur-
ring within 28 days of each other were considered to be a
single fatal event.
In order to harmonize the follow-up time for the three
conditions, incident cases of cancer and CVD ascertained
after 31 December 2007 were censored. In EPIC-CVD
centres with a censor date earlier than 31 December 2007,
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incident cases of cancer and T2D were censored at that
date. After exclusions of subjects from countries not par-
ticipating in EPIC-CVD or EPIC-InterAct, i.e. France,
Greece, and Norway, subjects with prevalent cancer, myo-
cardial infarction and angina, stroke, and T2D at baseline,
with missing information on T2D status at baseline, edu-
cation, smoking, and physical activity, a total of 291,778
study subjects (64% women) were included in the study
(Additional file 1: Figure S1).
Statistical methods
Cause-specific hazards for transitions to first conditions,
i.e. cancer, CVD, and T2D (including fatal events), and
subsequently to multimorbidity were modelled in a
multi-state framework with Cox proportional hazard
models [23] as outlined in Fig. 1. Deaths were censored
and not modelled as a separate outcome. When model-
ling transitions to first conditions, follow-up was to the
date of diagnosis of a first event, 31 December 2007 (or
earlier for centres with an earlier censoring date) or the
date of death, whichever occurred first. When modelling
transitions to multimorbidity, follow-up was considered
to be the date of a subsequent second event, 31 Decem-
ber 2007 (or earlier for centres with an earlier censoring
date), or the date of death, whichever occurred first.
Cause-specific hazard ratios (HR) and 95% confidence in-
tervals (CI), with age as the primary time variable, were esti-
mated for BMI (continuous, per 5 kg/m2), alcohol intake at
baseline (continuous, per 12 g/day, non-drinkers were mod-
elled with a separate indicator variable), physical activity
(continuous score expressing intensity: inactive, moderately
inactive, moderately active, active), smoking status (never
[reference], former, current), mrMDS (continuous, per 3-
unit increment), and the composite HLI score combining
all five lifestyle factors (continuous, per 3-unit increment).
The model was stratified by sex, age at inclusion (1-
year categories), recruitment centre, and transitions to
allow for transition-specific baseline hazards and esti-
mated transition-specific parameters [24]. Parameter es-
timates were further adjusted for an indicator variable to
define alcohol non-drinkers, education level (no school-
ing, primary [reference], secondary, and university or
more), height (continuous), and energy intake from non-
alcohol sources (kcal/day). In women, models were fur-
ther adjusted for menopausal status (pre-menopausal
[reference], peri-menopausal, post-menopausal, surgical)
and use of hormones (never [reference], ever, unknown).
Analyses were repeated in a priori defined subgroups.
Sensitivity analyses were carried out further adjusting for
hypertension (yes/no), determined as systolic blood pres-
sure of at least 140mmHg or diastolic blood pressure of
at least 80 mmHg and excluding, in turn, each compo-
nent of the HLI. In order to evaluate disease trajectories
according to the fatality of cancers, we divided total can-
cer into two groups based on their 5-year survival rates
[25]: (a) greater than 40% and (b) below 40%.
Cumulative incidence functions (CIFs) were estimated
to compute 10-year absolute risks to develop, in turn,
first cancer, CVD (both fatal and non-fatal), T2D, and
multimorbidity, according to the disease trajectories de-
scribed in Fig. 1. Non-fatal CVD events only were con-
sidered for the transition from CVD to multimorbidity.
Non-Markovian multi-state models that included time
since diagnosis for the transitions from any first condi-
tion to death or multimorbidity were implemented and
CIFs were estimated using the simLexis function of the
Fig. 1 Transitions from baseline to cancer, CVD, T2D, and subsequent cancer-cardiometabolic multimorbidity. Cancer refers to first malignant
tumours at any site excl. non-melanoma skin cancer. Deaths were censored and not modelled as a separate outcome. State-specific number of
events is reported in boxes, and transition-specific number of events and incidence rates per 1000 person-years (within brackets) are reported on
arrows. CVD cardiovascular disease, T2D type 2 diabetes
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R package Epi. CIFs were obtained for participants aged
55 and 65 years, separately for men and (post-meno-
pausal) women, comparing healthy (HLI = 15, 85th per-
centile) and unhealthy (HLI = 5, 4th percentile) lifestyle
behaviours. These values correspond, on average, to four
and one healthy behaviours on the simplified HLI, re-
spectively. CIFs were averaged over the distribution of
the observed adjustment factors (centre, level of educa-
tion, height, binary indicator for alcohol consumption,
total energy intake, and for women, use of hormones).
Competing risks analysis was accounted for in the esti-
mation of cause-specific hazard ratios and of CIFs. In
our study, participants at baseline were at risk of devel-
oping a first disease and at risk of dying. Similarly, par-
ticipants who developed a first chronic condition were at
risk of developing multimorbidity and at risk of dying.
Statistical tests were two-sided, and P values less than
0.05 were considered statistically significant. Statistical
analyses were performed with Stata 14.2 (College Sta-
tion, Texas, USA) and R [26].
Results
Country- and sex-specific baseline characteristics of the
study population are reported in Table 1. Among the 291,
778 study participants (64% women), the number of first in-
cident events ascertained within each NCD and after a me-
dian follow-up time of 10.7 years (IQR 9.3–12.1) were 22,
185 primary cancers (62% in women), 9016 CVD events
(42% in women), and 10,295 T2D events (50% in women)
(Fig. 1). After an overall median follow-up time of 11.0
years (IQR 9.8–12.3), 3244 participants (41% women) de-
veloped multimorbidity (Fig. 1). The most common multi-
morbidity pattern was CVD among cancer patients with a
crude incidence rate equal to 16.6 events per 1000 person-
years. Similarly common were T2D among CVD patients
(14.7/1000) or cancer among T2D patients (14.3/1000).
Among cancer patients, CVD and T2D were equally com-
mon (6.5/1000) (Additional file 1: Figure S2).
Associations with first NCDs
All five lifestyle factors were independently and statisti-
cally significantly associated with risk of developing a
first NCD with the exception of alcohol consumption,
where no association with T2D was observed (Fig. 2).
There was a marked heterogeneity in associations, which
was most pronounced for body fatness, as indicated by
BMI, and smoking status. Body fatness was strongly
positively associated with risk of T2D with a HR of 2.13
(95% CI, 2.10 to 2.17) per 5 kg/m2 higher BMI, and more
weakly with CVD (HR, 1.20 [95% CI, 1.17 to 1.23]) and
cancer (HR, 1.03 [95% CI, 1.01 to 1.05]) (Fig. 2). Current
smoking, as compared with never smoking, was strongly
positively associated with risk of CVD (HR, 2.15 [95%
CI, 2.04 to 2.27]), and somewhat weaker with cancer and
T2D with HRs of 1.37 (95% CI, 1.33 to 1.42) and 1.35
(95% CI, 1.29 to 1.42), respectively. There was less het-
erogeneity for physical activity, alcohol intake, and ad-
herence to the Mediterranean diet (Fig. 2).
The HLI was strongly inversely associated with risk of
CVD (HR, 0.77 [95% CI, 0.75 to 0.78] per 3 units) and T2D
(HR, 0.67 [95% CI, 0.66 to 0.69]), but less strongly associated
with risk of cancer (HR, 0.89 [95% CI, 0.88 to 0.91]) (Fig. 2).
Associations with multimorbidity of cancer and
cardiometabolic diseases
Associations between lifestyle factors and transitions to
multimorbidity of cancer and cardiometabolic diseases
after having had a first NCD are shown in Fig. 2. Little
heterogeneity in these transitions was observed with the
exception of multimorbidity related to BMI, where HRs
per 5 kg/m2 higher BMI varied between 1.08 (95% CI,
1.01 to 1.16) for multimorbidity after T2D to 1.63 (95%
CI, 1.51 to 1.76) for multimorbidity after cancer.
Physical activity was inversely associated with multi-
morbidity after T2D with a HR equal to 0.94 (95% CI,
0.88 to 1.00), but not after cancer or CVD. Alcohol con-
sumption was not associated with multimorbidity after
occurrence of a first chronic condition. Adherence to
the Mediterranean diet was inversely associated with risk
of multimorbidity among subjects who had developed
cancer with a HR of 0.89 (95% CI, 0.81 to 0.97) per 3
units higher adherence, but not after CVD or T2D.
The HLI was strongly inversely associated with risk of
multimorbidity with little heterogeneity after any of the
three NCDs (Fig. 2).
Ten-year absolute risk for NCDs and multimorbidity
Figure 3 shows the 10-year absolute risks to develop (i) a
first NCD, for example, cancer prior to any of the other
two conditions (CVD and T2D) accounting for death as a
competing event and (ii) subsequent multimorbidity, for
men and women at the age of 65 years, for low and high
adherence to healthy lifestyles. Despite the increased risk
of death among participants, particularly for cancer and
CVD patients, risk of developing a second condition was
large, in particular for those with poor lifestyle habits.
After T2D, the 10-year absolute risks for multimorbidity
were 40% and 25% for men and women, respectively, with
low adherence to healthy lifestyles (4th percentile of HLI),
and were 30% and 18% for men and women, respectively,
with healthy lifestyles (85th percentile of HLI). Multimor-
bidity risks after CVD events were similar, while lower
risks were observed in cancer patients. Overall, risks were
larger in men than in women.
Subgroup and sensitivity analyses
Findings were consistent in analyses stratified by sex,
age groups (≤ 55 and > 55 years at recruitment), and
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geographical regions (three groups: Spain, Italy vs.
Germany, the Netherlands, the UK vs. Denmark,
Sweden) (Additional file 1: Figure S3). The 10-year ab-
solute risks for men and women at the age of 55 years
are shown in Additional file 1: Figure S4. Results were
only marginally attenuated towards the null after
additional adjustment for hypertension and remained
statistically significant. Excluding in turn each compo-
nent of the HLI resulted in similar risk estimates
(Additional file 1: Figure S5). Findings were consistent
when we used the simplified version of the HLI, which
reflects associations per one additional healthy lifestyle
behaviour (Additional file 1: Figure S6). Correspond-
ing 10-year absolute risks to develop cancer, CVD,
T2D, and subsequent cancer-cardiometabolic multi-
morbidity for men and women at the age of 65 years
for values of the simplified HLI of 4 (adherence to four
lifestyle factors) and 1 (adherence to one lifestyle fac-
tor) are shown in Additional file 1: Figure S7.
Discussion
In a large cohort of more than 290,000 adult participants
from seven European countries, favourable lifestyle
habits, summarized by the HLI score, were strongly in-
versely associated with incident multimorbidity of cancer
and cardiometabolic diseases. Our absolute risk model
(CIFs) in particular assessed the burden of multimorbid-
ity among participants who experienced a first disease,
and quantified the preventive potential of healthy life-
style habits with regard to multimorbidity of cancer and
cardiometabolic diseases.
The findings of this study are consistent with evidence
from investigations that evaluated single NCDs with re-
gard to lifestyle exposures and obesity [9]. Few studies
investigated associations between lifestyle factors and
risk of multimorbidity [11–16]. In a Finnish population-
based cohort of 25–64-year-old men and women (n = 32,
972), smoking, physical inactivity, and a high BMI were
among the main pre-disposing factors of incident
Fig. 2 Lifestyle factors associated with risk of cancer, CVD, T2D, and subsequent cancer-cardiometabolic multimorbidity. Cancer refers
to first malignant tumours at any site excl. non-melanoma skin cancer. Deaths were censored and not modelled as a separate
outcome. a Cox proportional hazard models, stratified by age at inclusion (1-year categories), sex, centre, and transition, in a clock-
forward multi-state analysis with age as primary time variable, mutually adjusted lifestyle factors and further adjustment for education
level (no schooling, primary, secondary, and university or more), height (continuous), an indicator of alcohol use (no/yes), total energy
intake (kcal/day), and use of hormones and menopausal status in women. b Same as a, but the five lifestyle factors were combined in
the healthy lifestyle index (HLI); the HLI ranges from 0 to 20 units, with greater scores reflecting healthy lifestyles. CVD cardiovascular
disease, T2D type 2 diabetes
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multimorbidity defined as the co-occurrence of at least
two among T2D, CVD, asthma, cancer, and arthritis
[12]. In a small English cohort that included adults aged
≥ 50 years, positive associations with incident multimor-
bidity, defined as ≥ 2 chronic conditions including T2D,
CVDs, cancer, and others, in relation to smoking, higher
alcohol consumption, lower physical activity, lower fruit
and vegetable intake, and obesity were found [11, 14].
Among 13,714 Australian women aged 45–50 years at
enrolment, obesity, hypertension, physical inactivity,
smoking, or having other chronic conditions were also
significantly associated with increased odds of accumu-
lating cardiometabolic multimorbidity, defined as the co-
occurrence of at least two morbid conditions among
T2D, coronary heart disease, and stroke [16]. A large
pooling study of prospective cohorts from the USA and
Europe that included 120,813 adults showed that the risk
of cardiometabolic multimorbidity was positively associ-
ated with BMI, with a relative risk of 1.9 (95% CI, 1.8 to
2.3) per 5 kg/m2 increment [13]. In contrast, lifestyle fac-
tors were not associated with 3-year incidence of multi-
morbidity among community-dwelling older adults 75
years and older [15]. Our findings are largely consistent
with previous studies, but also go beyond in that we de-
fined multimorbidity as developing subsequently two in-
cident NCDs. This approach allowed the quantification
of the preventive potential with regard to multimorbidity
of cancer and cardiometabolic diseases.
The 10-year absolute risk estimates for cancer-
cardiometabolic multimorbidity ranged between 5 and 17%
for cancer patients, and between 20 and 40% for T2D and
CVD patients, depending on sex and adherence to healthy
lifestyles. In this respect, it is worthwhile mentioning that
once an individual develops a cancer, the competing risk of
mortality is comparatively larger than among individuals
experiencing T2D or non-fatal CVD. This explains why the
absolute risk of developing multimorbidity was lower
among cancer patients than among CVD or T2D patients.
Fig. 3 Cumulative incidence functions (CIFs) to develop cancer, CVD, T2D, and subsequent cancer-cardiometabolic multimorbidity. Cancer refers to first
malignant tumours at any site excl. non-melanoma skin cancer. Deaths were censored and not modelled as a separate outcome. Computed for 65 years
old men (dotted) and women (continuous) for values of the healthy lifestyle index (HLI) of 15 (healthy, 85th percentile in green) and 5 (unhealthy, 4th
percentile in red); the HLI ranges from 0 to 20 units, with greater scores reflecting healthy lifestyles. The model was stratified for centre, sex, and adjusted
for education level (no schooling, primary, secondary, and university or more), height (continuous), binary indicator of alcohol use (no/yes), total energy
intake (kcal/day), and use of hormones and menopausal status in women. CVD cardiovascular disease, T2D type 2 diabetes
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We further evaluated the risk of multimorbidity in patients
developing cancer in sites with 5-year survival below or
above 40% [25]. This supplementary analysis indicate that
pre-diagnostic healthy lifestyles were particularly beneficial
for patients developing cancer with longer survival, where,
for example, the 10-year absolute risk of multimorbidity for
65-year old men with healthy and unhealthy lifestyle pro-
files were 11% and 24%, respectively (Additional file 1: Fig-
ure S8). The pronounced sex differences in risk patterns
are likely to reflect larger prevalence of key risk factors in
men than women. Importantly, the change in absolute risks
related to healthy vs. unhealthy lifestyles indicate the pre-
ventive potential in terms of risk stratification for multi-
morbidity of cancer and cardiometabolic diseases. Many
modifiable risk factors, including obesity, smoking, and
physical inactivity are associated with multiple cancer types,
T2D, and CVD, and could be the target of intervention
strategies aiming at controlling multiple conditions, beyond
efforts focusing on one disease only [10]. A population-
based cohort study in the Netherlands showed that partici-
pants aged 45 years and older who did not smoke, where of
normal weight, and with no hypertension at baseline spent
21.6% of their remaining lifetime with one or more NCDs,
compared to 31.8% of their remaining life for participants
with all of these risk factors at baseline [27].
Exposure to risk factors that are associated with more
than one disease is one plausible explanation for the
clustering of NCDs in individuals and indicate common
etiological pathways [28, 29]. For example, obesity pro-
motes systemic inflammation, a well-described pathway for
the development of cancer [30], CVD [31], and T2D [32].
This study has several strengths. First, we used individual-
level data from a large prospective cohort of European
adults using validated assessments of cancer, CVD and T2D,
together with study participants’ pre-diagnostic exposure to
several lifestyle factors. Although EPIC was designed to as-
sess the occurrence of cancer, this study capitalized on the
ascertainment of incident CVD and T2D events and related
validation efforts carried out within the EPIC-InterAct [18]
and EPIC-CVD [19] studies. Second, it is the largest study
to date to estimate associations between modifiable expo-
sures and the risk of multimorbidity. Third, associations
were modelled in a multi-state framework accounting for
the sequence of incident chronic conditions.
The study findings need to be interpreted in light of
the following limitations. First, information on lifestyle
exposures assessed at baseline was used in this study,
while potential changes in modifiable behaviours during
lifetime, particularly after the diagnosis of NCDs, could
not be accounted for in the investigation. Nevertheless,
our results indicate associations between pre-diagnostic
lifestyle habits and risk of NCDs and multimorbidity, as-
suming that exposure profiles prior to disease onset may
have an impact on subsequent morbidities. Potential
improvements in health behaviours after diagnosis of a
first NCD would most likely have led to an underestima-
tion of observed relative and absolute risks. Moreover, it
has been shown that in the absence of interventions, the
vast majority of individuals do not make major lifestyle
changes following diagnosis of a serious chronic disease
[33]. Second, associations between risk factors and the
risk of multimorbidity after the occurrence of a first dis-
ease may be affected by collider bias as exemplified in the
obesity paradox [34, 35], and such a bias tends to weaken
observed associations. In our study, however, risk esti-
mates were in the expected direction and magnitude after
conditioning on the first disease, suggesting that collider
bias was of limited concern in our study. An additional
limitation was the lack of treatment data after a first
NCD. Metformin, which is recommended as first-line
therapy in most T2D patients, has been found to decrease
cardiovascular risk and possibly some cancers [32, 36]. In
contrast, the increased risk of cardiac diseases following
cancer therapy is well recognized [37]. However, assum-
ing that treatment is independent of lifestyle, then our
observed associations should be unaffected by treatment.
Finally, although our relative risk estimates should be
generalizable, the absolute risks associated with lifestyle
factors heavily depend on the underlying risks of the
study population, which however may be different in the
general population.
In conclusion, healthy lifestyle behaviours were strongly
inversely associated with the risk of cancer and cardiomet-
abolic diseases. Healthy lifestyles prior to a first NCD may
also contribute to a favourable prognosis of these diseases
by reducing risk of multimorbidity. These findings provide
strong support to public health recommendations to ad-
here to multiple healthy lifestyle factors.
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